Ispire Forms Joint Venture with Shandong Jincheng Pharma
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Ispire Technology has entered into a joint venture with Shandong Jincheng Pharma, a global pharmaceutical company, to manufacture and commercialize nicotine pouch products. The joint venture marks Ispire's entry into the oral nicotine category. Jincheng Pharma will contribute manufacturing equipment, technical expertise, and nicotine pouch materials. Jincheng Pharma is a diversified pharmaceutical company with approximately 3,800 employees and more than 30 affiliated companies worldwide. The company is engaged in the research, development, production, and commercialization of pharmaceutical intermediates, active pharmaceutical ingredients, finished pharmaceutical products, and health-related products. The company expects initial production to be supported by existing commercial relationships and intends to pursue additional business development opportunities within the oral nicotine segment as part of its broader international nicotine platform strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISPR
Wall Street analysts forecast ISPR stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.790
Low
6.50
Averages
6.50
High
6.50
Current: 1.790
Low
6.50
Averages
6.50
High
6.50
No data
About ISPR
Ispire Technology Inc. is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded and non-branded e-cigarettes and vaping hardware products in both the nicotine and cannabis spaces. The Company’s nicotine products are marketed under the Aspire brand name, primarily through a global distribution network. It sells its cannabis vaping hardware in the United States, Canada, South Africa, and Germany. Its cannabis products are marketed under the Ispire brand name, primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies, including multi- and single-state operators, brand owners, and co-packers. Its product portfolio includes E-Cigarette Products and Cannabis Products. The Company's open system devices are marketed under brands such as Nautilus and Zestquest and closed system products are marketed under licensed brands including BRKFST and Hidden Hills Club.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Railroad Stocks Underperform on Thursday
- Sector Decline: Railroad stocks collectively fell by approximately 1.5% on Thursday, indicating a weakening market confidence in the sector, which could negatively impact investor expectations for future earnings.
- Norfolk Southern Underperformance: Norfolk Southern's shares dropped by about 4.8%, making it the worst performer in the industry, suggesting potential operational or market challenges facing the company.
- Union Pacific Decline: Union Pacific's stock fell by around 4%, further exacerbating the overall weakness in the railroad sector, which may lead investors to reassess their investment strategies.
- Market Sentiment Impact: The decline in railroad stocks contrasts with broader market trends, potentially raising concerns about economic slowdown and affecting investment inflows into related industries.
See More
Ispire Partners with Jincheng Pharma to Enter Growing Nicotine Market
- Strategic Partnership: Ispire has formed a joint venture with Jincheng Pharma to manufacture and commercialize nicotine pouch products, marking Ispire's entry into the rapidly growing oral nicotine market, which is projected to exceed $40 billion by 2033, significantly broadening the company's product portfolio.
- Market Potential: According to Grand View Research, the nicotine pouch market was approximately $7 billion in 2025 and is expected to grow at nearly 25% annually, providing Ispire with substantial market opportunities to quickly establish a new revenue stream.
- Enhanced Production Capacity: Jincheng Pharma will contribute manufacturing equipment and technical expertise to support Ispire's rapid production ramp-up, and by leveraging Ispire's strengths in precision dosing and global distribution, the partnership aims to enhance product differentiation in a competitive market.
- Global Expansion: This collaboration not only strengthens Ispire's manufacturing capabilities but also utilizes Jincheng Pharma's customer relationships and pharmaceutical expertise to ensure the rapid production of high-quality nicotine pouches, further advancing Ispire's development within its international nicotine platform strategy.
See More
Ispire Forms Joint Venture with Jincheng Pharma for Nicotine Pouches
- Market Expansion: Ispire's joint venture with Jincheng Pharma marks its entry into the rapidly growing oral nicotine market, projected to exceed $40 billion by 2033, significantly broadening Ispire's product portfolio beyond vaping hardware.
- Production Capacity Boost: The joint venture will leverage Jincheng Pharma's pharmaceutical equipment and technical expertise to rapidly scale nicotine pouch production, enabling swift commercialization and enhancing Ispire's position in a competitive market.
- Strategic Collaboration: This partnership combines Ispire's strengths in precision dosing and global distribution, expected to create new revenue streams and advance its broader nicotine platform strategy.
- Industry Leadership: Jincheng Pharma selected Ispire as a partner due to its reputation for high-quality manufacturing and robust global compliance capabilities, indicating that Ispire's leadership in the global nicotine market will be further solidified.
See More
Ispire Technology Q3 2026 Earnings Call Insights
- Financial Performance Overview: Ispire reported revenue of $18.7 million for Q3 2026, down from $26.2 million in Q3 2025, primarily due to seasonal factory downtime during the Chinese New Year, reflecting the company's resilience amid market fluctuations.
- Cash Flow Status: The company ended the quarter with $18 million in cash, an increase of $468,000 sequentially, reinforcing management's confidence in achieving cash flow positivity in the second half of 2026, indicating a steady recovery towards profitability.
- Malaysia Manufacturing Platform: Ispire's Malaysia manufacturing platform is now operational, expected to provide a 25% tariff advantage, enhancing the company's competitiveness in the $73 billion global vape market and laying the groundwork for future customer acquisition and margin improvement.
- Vapor ODM Initiative: Plans are underway to launch the Vapor ODM initiative in July, initially targeting small and mid-sized brands with larger brand opportunities anticipated for 2027, showcasing the company's strategic positioning in market segmentation and product innovation.
See More
Ispire Technology Reports Q3 Earnings with Revenue Decline
- Earnings Performance: Ispire Technology reported a Q3 GAAP EPS of -$0.17 with revenue of $18.7 million, reflecting a significant year-over-year decline of 28.6%, indicating pressure in market competition and challenges in profitability.
- Cash Flow Status: As of March 31, 2026, the company held $18 million in cash and only $0.9 million in working capital, suggesting difficulties in cash flow management that could impact future operations and investment capabilities.
- FDA Approval Progress: Ispire Technology is currently awaiting FDA approval, a critical milestone that will directly affect the timing of product launches and market competitiveness; if approved, it could open new revenue streams for the company.
- Market Reaction: Due to the poor financial performance, investor confidence in Ispire Technology has been shaken, potentially leading to further downward pressure on the stock price, which may affect the company's future financing and strategic development.
See More
Ispire Technology to Host Earnings Call on May 7, 2026
- Earnings Call Announcement: Ispire Technology will host an earnings conference call on May 7, 2026, at 8:00 am ET to discuss its financial results for the third quarter ended March 31, 2026, aiming to provide investors with insights into its latest financial performance and future outlook.
- Participation Details: Participants can dial in using the provided numbers and request the “Ispire Technology Call” to listen to the meeting, and the call will also be webcast live, ensuring that all interested parties can access real-time information.
- Playback Information: After the call, a playback will be available by dialing 1-844-512-2921 or 1-412-317-6671 with passcode 10208863, and this service will be available until 11:59 pm ET on May 21, 2026, allowing investors who missed the live event to catch up.
- Company Overview: Ispire Technology focuses on the research, development, and sales of e-cigarettes and cannabis vaping products, holding over 400 patents globally, with its branded products sold worldwide, showcasing its strong competitive position and market influence in the industry.
See More
Railroad Stocks Underperform on Thursday
- Sector Decline: Railroad stocks collectively fell by approximately 1.5% on Thursday, indicating a weakening market confidence in the sector, which could negatively impact investor expectations for future earnings.
- Norfolk Southern Underperformance: Norfolk Southern's shares dropped by about 4.8%, making it the worst performer in the industry, suggesting potential operational or market challenges facing the company.
- Union Pacific Decline: Union Pacific's stock fell by around 4%, further exacerbating the overall weakness in the railroad sector, which may lead investors to reassess their investment strategies.
- Market Sentiment Impact: The decline in railroad stocks contrasts with broader market trends, potentially raising concerns about economic slowdown and affecting investment inflows into related industries.
See More
Ispire Partners with Jincheng Pharma to Enter Growing Nicotine Market
- Strategic Partnership: Ispire has formed a joint venture with Jincheng Pharma to manufacture and commercialize nicotine pouch products, marking Ispire's entry into the rapidly growing oral nicotine market, which is projected to exceed $40 billion by 2033, significantly broadening the company's product portfolio.
- Market Potential: According to Grand View Research, the nicotine pouch market was approximately $7 billion in 2025 and is expected to grow at nearly 25% annually, providing Ispire with substantial market opportunities to quickly establish a new revenue stream.
- Enhanced Production Capacity: Jincheng Pharma will contribute manufacturing equipment and technical expertise to support Ispire's rapid production ramp-up, and by leveraging Ispire's strengths in precision dosing and global distribution, the partnership aims to enhance product differentiation in a competitive market.
- Global Expansion: This collaboration not only strengthens Ispire's manufacturing capabilities but also utilizes Jincheng Pharma's customer relationships and pharmaceutical expertise to ensure the rapid production of high-quality nicotine pouches, further advancing Ispire's development within its international nicotine platform strategy.
See More
Ispire Forms Joint Venture with Jincheng Pharma for Nicotine Pouches
- Market Expansion: Ispire's joint venture with Jincheng Pharma marks its entry into the rapidly growing oral nicotine market, projected to exceed $40 billion by 2033, significantly broadening Ispire's product portfolio beyond vaping hardware.
- Production Capacity Boost: The joint venture will leverage Jincheng Pharma's pharmaceutical equipment and technical expertise to rapidly scale nicotine pouch production, enabling swift commercialization and enhancing Ispire's position in a competitive market.
- Strategic Collaboration: This partnership combines Ispire's strengths in precision dosing and global distribution, expected to create new revenue streams and advance its broader nicotine platform strategy.
- Industry Leadership: Jincheng Pharma selected Ispire as a partner due to its reputation for high-quality manufacturing and robust global compliance capabilities, indicating that Ispire's leadership in the global nicotine market will be further solidified.
See More
Ispire Technology Q3 2026 Earnings Call Insights
- Financial Performance Overview: Ispire reported revenue of $18.7 million for Q3 2026, down from $26.2 million in Q3 2025, primarily due to seasonal factory downtime during the Chinese New Year, reflecting the company's resilience amid market fluctuations.
- Cash Flow Status: The company ended the quarter with $18 million in cash, an increase of $468,000 sequentially, reinforcing management's confidence in achieving cash flow positivity in the second half of 2026, indicating a steady recovery towards profitability.
- Malaysia Manufacturing Platform: Ispire's Malaysia manufacturing platform is now operational, expected to provide a 25% tariff advantage, enhancing the company's competitiveness in the $73 billion global vape market and laying the groundwork for future customer acquisition and margin improvement.
- Vapor ODM Initiative: Plans are underway to launch the Vapor ODM initiative in July, initially targeting small and mid-sized brands with larger brand opportunities anticipated for 2027, showcasing the company's strategic positioning in market segmentation and product innovation.
See More
Ispire Technology Reports Q3 Earnings with Revenue Decline
- Earnings Performance: Ispire Technology reported a Q3 GAAP EPS of -$0.17 with revenue of $18.7 million, reflecting a significant year-over-year decline of 28.6%, indicating pressure in market competition and challenges in profitability.
- Cash Flow Status: As of March 31, 2026, the company held $18 million in cash and only $0.9 million in working capital, suggesting difficulties in cash flow management that could impact future operations and investment capabilities.
- FDA Approval Progress: Ispire Technology is currently awaiting FDA approval, a critical milestone that will directly affect the timing of product launches and market competitiveness; if approved, it could open new revenue streams for the company.
- Market Reaction: Due to the poor financial performance, investor confidence in Ispire Technology has been shaken, potentially leading to further downward pressure on the stock price, which may affect the company's future financing and strategic development.
See More
Ispire Technology to Host Earnings Call on May 7, 2026
- Earnings Call Announcement: Ispire Technology will host an earnings conference call on May 7, 2026, at 8:00 am ET to discuss its financial results for the third quarter ended March 31, 2026, aiming to provide investors with insights into its latest financial performance and future outlook.
- Participation Details: Participants can dial in using the provided numbers and request the “Ispire Technology Call” to listen to the meeting, and the call will also be webcast live, ensuring that all interested parties can access real-time information.
- Playback Information: After the call, a playback will be available by dialing 1-844-512-2921 or 1-412-317-6671 with passcode 10208863, and this service will be available until 11:59 pm ET on May 21, 2026, allowing investors who missed the live event to catch up.
- Company Overview: Ispire Technology focuses on the research, development, and sales of e-cigarettes and cannabis vaping products, holding over 400 patents globally, with its branded products sold worldwide, showcasing its strong competitive position and market influence in the industry.
See More
